MCID: NRN004
MIFTS: 55

Neuroendocrine Tumor

Categories: Endocrine diseases, Neuronal diseases, Cancer diseases

Aliases & Classifications for Neuroendocrine Tumor

MalaCards integrated aliases for Neuroendocrine Tumor:

Name: Neuroendocrine Tumor 12 14
Neuroendocrine Tumors 52 42 69
Carcinoma, Neuroendocrine 42 69
Neuroendocrine Carcinoma 12 14
Neuroendocrine Neoplasm 12 29
Carcinoma Neuroendocrine 52

Classifications:



External Ids:

Disease Ontology 12 DOID:169 DOID:1800
ICD10 33 D3A.8
ICD9CM 35 209 209-209.99
NCIt 47 C3809 C3773

Summaries for Neuroendocrine Tumor

Disease Ontology : 12 A carcinoma that derives from neuroendocrine cells.

MalaCards based summary : Neuroendocrine Tumor, also known as neuroendocrine tumors, is related to neuroendocrine tumor of the colon and paraganglioma. An important gene associated with Neuroendocrine Tumor is CHGA (Chromogranin A), and among its related pathways/superpathways are Neuroscience and Neural Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Afinitor and Sutent have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and liver, and related phenotypes are behavior/neurological and endocrine/exocrine gland

Wikipedia : 72 Neuroendocrine tumors (NETs) are neoplasms that arise from cells of the endocrine (hormonal) and nervous... more...

Related Diseases for Neuroendocrine Tumor

Diseases related to Neuroendocrine Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 358)
id Related Disease Score Top Affiliating Genes
1 neuroendocrine tumor of the colon 34.2 CALCA GAST
2 paraganglioma 30.6 CHGA SDHD SST
3 cystadenoma 29.2 ENO2 NCAM1 NTS SYP
4 pheochromocytoma 29.1 ASCL1 CALCA CHGA CHGB ENO2 MEN1
5 lung cancer 26.3 ASCL1 CHGA ENO2 GRP KRT20 NCAM1
6 pancreatic neuroendocrine tumor 12.2
7 pulmonary neuroendocrine tumor 12.2
8 neuroendocrine carcinoma of the cervix 12.1
9 gastrointestinal neuroendocrine tumor 12.0
10 anal neuroendocrine tumor 12.0
11 esophageal neuroendocrine tumor 12.0
12 gastric neuroendocrine tumor 11.9
13 ileal neuroendocrine tumor 11.9
14 thymic neuroendocrine tumor 11.9
15 gastro-enteropancreatic neuroendocrine tumor 11.9
16 low-grade neuroendocrine tumor of the corpus uteri 11.9
17 laryngeal neuroendocrine tumor 11.9
18 classic neuroendocrine tumor of appendix 11.9
19 neuroendocrine tumor of the appendix 11.8
20 hereditary neuroendocrine tumor of small intestine 11.8
21 small intestine carcinoid neuroendocrine tumor 11.8
22 middle ear neuroendocrine tumor 11.8
23 gallbladder neuroendocrine tumor 11.8
24 jejunal neuroendocrine tumor 11.8
25 neuroendocrine tumor of the anal canal 11.8
26 familial gastric type 1 neuroendocrine tumor 11.8
27 insulinoma 11.4
28 gastrinoma 11.2
29 retinoblastoma 11.2
30 von hippel-lindau syndrome 11.2
31 pancreatic cancer 11.1
32 goblet cell carcinoid 11.1
33 carcinoid syndrome 11.1
34 rectum neuroendocrine neoplasm 11.0
35 autoimmune enteropathy 10.9 CHGA GAST
36 malignant ovarian mixed epithelial neoplasm 10.9 CHGA SYP
37 wegmann jones smith syndrome 10.9 CALCA SST
38 2q31.1 microdeletion syndrome 10.9 ENO2 SYP
39 nutritional optic neuropathy 10.9 GAST SST
40 oral leukoedema 10.8 SST SSTR2
41 ferguson-smith tumor 10.8 ENO2 GAST
42 spinal cord ependymoma 10.8 CHGA SYP
43 pancreas adenocarcinoma 10.8
44 hereditary paraganglioma-pheochromocytoma syndromes 10.8
45 adrenal carcinoma 10.8
46 phaeochromocytoma 10.8
47 signet ring cell intrahepatic cholangiocarcinoma 10.8 CHGA SYP
48 primary syphilis 10.8 CHGA GAST SST
49 bone giant cell sarcoma 10.8 CHGA GAST SST
50 breast apocrine carcinoma in situ 10.8 SST SYP

Graphical network of the top 20 diseases related to Neuroendocrine Tumor:



Diseases related to Neuroendocrine Tumor

Symptoms & Phenotypes for Neuroendocrine Tumor

MGI Mouse Phenotypes related to Neuroendocrine Tumor:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.9 ASCL1 CCK ENO2 GRP NCAM1 NKX2-1
2 endocrine/exocrine gland MP:0005379 9.61 ASCL1 CCK CHGA CHGB GAST INSM1
3 nervous system MP:0003631 9.44 NCAM1 NKX2-1 NTS SDHD SST SSTR2

Drugs & Therapeutics for Neuroendocrine Tumor

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Afinitor 17 46 EVEROLIMUS Novartis March 2009
2
Sutent 17 46 SUNITINIB MALATE Pfizer May 2011/ January 2006

Drugs for Neuroendocrine Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 653)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 61825-94-3 5310940 9887054 43805 6857599
2
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
3
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 4342-03-4 5351166
4
Vindesine Approved Phase 4 59917-39-4, 53643-48-4 40839
5
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1 347396-82-1 459903
6
Somatostatin Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 38916-34-6, 51110-01-1 53481605
7
Everolimus Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 159351-69-6 6442177
8
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 22916-47-8 4189
9
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 53123-88-9 5284616 6436030 46835353
10
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
11
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 33069-62-4 36314
12
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 99011-02-6 57469
13
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 83150-76-9 383414 6400441
14
Pancrelipase Approved Phase 4,Phase 1,Phase 2,Early Phase 1 53608-75-6
15
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102
16
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 124-94-7 31307
17
nivolumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 946414-94-4
18
Dasatinib Approved, Investigational Phase 4,Phase 2,Phase 1 302962-49-8 3062316
19
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 284461-73-0 216239 406563
20
Trametinib Approved Phase 4,Phase 3,Phase 2,Phase 1 871700-17-3 11707110
21
Aldesleukin Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 85898-30-2, 110942-02-4
22 lanreotide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 108736-35-2
23
Etanercept Approved, Investigational Phase 4 185243-69-0
24
Bortezomib Approved, Investigational Phase 4,Phase 2,Phase 1 179324-69-7 387447 93860
25
Gefitinib Approved, Investigational Phase 4,Phase 2 184475-35-2 123631
26
Ramucirumab Approved, Investigational Phase 4,Phase 2,Phase 1 947687-13-0
27
Vorinostat Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 149647-78-9 5311
28
Doxazosin Approved Phase 4,Phase 3 74191-85-8 3157
29
Phenoxybenzamine Approved Phase 4,Phase 3 59-96-1 4768
30
Aminolevulinic acid Approved Phase 4 106-60-5 137
31
Crizotinib Approved Phase 4,Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
32
Palbociclib Approved Phase 4,Phase 1,Phase 2 571190-30-2 11431660 5005498 5330286
33
Ceritinib Approved Phase 4,Phase 2 1032900-25-6
34
Olaparib Approved Phase 4 763113-22-0 23725625
35 Pancreatic Polypeptide Investigational Phase 4,Phase 2,Phase 3,Phase 1 59763-91-6
36
Lactitol Investigational Phase 4,Phase 1,Phase 2 585-86-4 3871
37
Lapatinib Approved March 2007, Investigational Phase 4,Phase 2,Early Phase 1 231277-92-2, 388082-78-8 208908 9941095
38 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
39 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
40 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1
41 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
42 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1
43 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
44 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
45 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
46 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
48 Antifungal Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
49 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
50 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 2448)

id Name Status NCT ID Phase Drugs
1 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376 Phase 4
2 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
3 Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma Unknown status NCT00226473 Phase 4 Cisplatin, Vindesine, Dacarbazine (drugs)
4 Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Unknown status NCT00540930 Phase 4 Ranibizumab
5 Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients Completed NCT02075606 Phase 4 lanreotide acetate
6 Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced Neuroendocrine Tumors Completed NCT01595009 Phase 4 RAD001
7 Somatuline Autogel Preference and Health Economy Study Completed NCT00681187 Phase 4 lanreotide (Autogel formulation)
8 RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation Completed NCT01317615 Phase 4 RAD001;Paclitaxel;Carboplatin
9 Can We Miss Pigmented Lesions in Psoriasis Patients? Completed NCT01053819 Phase 4 etanercept
10 Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab Completed NCT01515189 Phase 4
11 Post-Operative Drainage Following Lymph Node Dissection Completed NCT00324272 Phase 4 Fibrin Sealant (Tisseel) used in the Experimental Arm.
12 Long Term Results of Combined Transpupillary Thermotherapy (TTT) Indocyanine Green (ICG) Based Photodynamic Therapy (PDT) in Choroidal Melanoma Completed NCT01253759 Phase 4
13 Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy Completed NCT01959711 Phase 4
14 Effect of Topical Imiquimod on Lentigo Maligna Completed NCT01161888 Phase 4 Imiquimod
15 A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide Recruiting NCT03289741 Phase 4 Octreotide;LAR Lanreotide
16 Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China Recruiting NCT02842749 Phase 4 everolimus
17 Nonfunctional Pancreatic NET and PET Imaging Recruiting NCT02621541 Phase 4
18 Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study. Recruiting NCT01789281 Phase 4 Everolimus;Sandostatin LAR Depot
19 Radiolabeled Molecules for Medullary Thyroid Cancer Recruiting NCT01915485 Phase 4
20 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
21 A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer Recruiting NCT01896479 Phase 4 Cabozantinib (XL184) 140 mg;Cabozantinib (XL184) 60 mg;Placebo tablet;Placebo capsule
22 Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function Recruiting NCT02415257 Phase 4 Gentamicin
23 Gentamicin Treatment Prior to Schwannoma Surgery - Residual Function Recruiting NCT02379754 Phase 4 Gentamicins
24 Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma Recruiting NCT02451488 Phase 4 GM-CSF
25 Phenoxybenzamine Versus Doxazosin in PCC Patients Recruiting NCT01379898 Phase 4 Phenoxybenzamine;Doxazosin
26 Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream Recruiting NCT02685592 Phase 4 5-aminolevulinic acid nanoemulsion
27 A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525550 Phase 4 sunitinib
28 Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors Active, not recruiting NCT02759718 Phase 4
29 Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET Active, not recruiting NCT03083210 Phase 4 Lanreotide
30 Stereotactic Body Radiotherapy for Liver Tumors Active, not recruiting NCT01347333 Phase 4
31 TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy Active, not recruiting NCT02379000 Phase 4 Triamcinolone Acetonide
32 An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma Active, not recruiting NCT01898585 Phase 4 Zelboraf
33 A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma. Active, not recruiting NCT02068196 Phase 4 Ipilimumab
34 Stereotactic Body Radiotherapy for Head and Neck Tumors Active, not recruiting NCT01344356 Phase 4
35 Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies Active, not recruiting NCT02626065 Phase 4 Nivolumab
36 Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma Not yet recruiting NCT02645149 Phase 4 Standard therapy or clinical trial;Matched targeted therapy;Trametinib and / or supportive care
37 HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma Terminated NCT01856023 Phase 4 High Dose Interleukin-2;Ipilimumab
38 HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Terminated NCT01683188 Phase 4 vemurafenib + HD IL-2
39 Pasireotide Treatment for Neuroendocrine Tumor Withdrawn NCT02779257 Phase 4 Pasireotide;Diazoxide
40 Study to Investigate the Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut Unknown status NCT00171873 Phase 3 Octreotide LAR (Long-acting release);Placebo
41 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
42 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Unknown status NCT01373736 Phase 3 123I-meta-iodobenzylguanidine
43 The Role of Inhalations of Tranexamic Acid in Patients With Hemoptysis Unknown status NCT01496196 Phase 3 tranexamic acid;tranexamic acid
44 Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer Unknown status NCT00704730 Phase 3 XL184;Placebo
45 Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver Unknown status NCT00039234 Phase 3 histamine dihydrochloride
46 Vaccine Therapy in Treating Patients With Primary Stage II Melanoma Unknown status NCT00005052 Phase 3
47 Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma Unknown status NCT00006249 Phase 3
48 High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma Unknown status NCT00002763 Phase 3
49 Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients Unknown status NCT01861938 Phase 2, Phase 3
50 Stereotactic Radiation in Vestibular Schwannoma Unknown status NCT01449604 Phase 3

Search NIH Clinical Center for Neuroendocrine Tumor

Cochrane evidence based reviews: neuroendocrine tumors

Genetic Tests for Neuroendocrine Tumor

Genetic tests related to Neuroendocrine Tumor:

id Genetic test Affiliating Genes
1 Neuroendocrine Neoplasm 29

Anatomical Context for Neuroendocrine Tumor

MalaCards organs/tissues related to Neuroendocrine Tumor:

39
Lung, Brain, Liver, Thyroid, Skin, Kidney, Lymph Node

Publications for Neuroendocrine Tumor

Articles related to Neuroendocrine Tumor:

(show top 50) (show all 1172)
id Title Authors Year
1
Activation of the ileal neuroendocrine tumor cell line P-STS by acetylcholine is amplified by histamine: role of H3R and H4R. ( 28465562 )
2017
2
Hepatobiliary and Pancreatic: A rare case of a well-differentiated neuroendocrine tumor in the bile duct with spontaneous regression diagnosed by EUS-FNA. ( 28052461 )
2017
3
Impact of Therapy Sequence with Alkylating Agents and MGMT Status in Patients with Advanced Neuroendocrine Tumors. ( 28476818 )
2017
4
Combined 18F-FDG PET/CT and 68Ga DOTATATE PET/CT "Superscan" in Metastatic Pancreatic Neuroendocrine Tumor. ( 27997429 )
2017
5
Pancreatic Neuroendocrine Tumor Abnormally Secreting Procalcitonin. ( 27977635 )
2017
6
Efficacy of Peptide Receptor Radionuclide Therapy in a United States-Based Cohort of Metastatic Neuroendocrine Tumor Patients: Single-Institution Retrospective Analysis. ( 28902781 )
2017
7
Sarcoidosis mimicking metastatic progression of pancreatic neuroendocrine tumor: A case report. ( 28658123 )
2017
8
Application of (68)Ga-DOTA-TATE PET/CT in metastatic neuroendocrine tumor of gastrointestinal origin. ( 28042252 )
2017
9
Late onset asymptomatic pancreatic neuroendocrine tumor - A case report on the phenotypic expansion for MEN1. ( 28736585 )
2017
10
Gastric neuroendocrine tumor with hypergastrinemia following type B chronic atrophic gastritis: a case report. ( 28163290 )
2017
11
Laparoscopic total pancreatectomy for multiple endocrine neoplasia type 1 syndrome-associated multifocal, non-functioning pancreatic neuroendocrine tumor: A case report. ( 28589571 )
2017
12
Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE for Metastatic Neuroendocrine Tumor Occurring in Association with Multiple Endocrine Neoplasia Type 1 and Cushing's Syndrome. ( 28553179 )
2017
13
Peripancreatic paraganglioma mimics pancreatic/gastrointestinal neuroendocrine tumor on fine needle aspiration: Report of two cases and review of the literature. ( 28560856 )
2017
14
Single-stage laparoscopic adrenalectomy for pheochromocytoma and enucleation of a pancreatic neuroendocrine tumor in Von Hippel-Lindau disease: A case report. ( 28515932 )
2017
15
Pancreatic neuroendocrine tumor: prediction of the tumor grade using CT findings and computerized texture analysis. ( 28766979 )
2017
16
CD133 expression in well-differentiated pancreatic neuroendocrine tumors: a potential predictor of progressive clinical courses. ( 27864124 )
2017
17
Pancreatic neuroendocrine tumor in a patient with a TSC1 variant: case report and review of the literature. ( 28887784 )
2017
18
Loss of Progesterone Receptor Expression Is an Early Tumorigenesis Event Associated with Tumor Progression and Shorter Survival in Pancreatic Neuroendocrine Tumor Patients. ( 28597868 )
2017
19
Magnetic Resonance Imaging of Neuroendocrine Tumor Hepatic Metastases: Does Hepatobiliary Phase Imaging Improve Lesion Conspicuity and Interobserver Agreement of Lesion Measurements? ( 28902795 )
2017
20
Synchronous intraductal papillary mucinous neoplasm and a pancreatic neuroendocrine tumor: more than a coincidence? ( 28724304 )
2017
21
Identifying and Prioritizing Gaps in Neuroendocrine Tumor Research: A Modified Delphi Process With Patients and Health Care Providers to Set the Research Action Plan for the Newly Formed Commonwealth Neuroendocrine Tumor Collaboration. ( 28831446 )
2017
22
The impact of SSTR-directed PET/CT on the management of patients with neuroendocrine tumor: A systematic review and meta-analysis. ( 28082438 )
2017
23
Insulinoma-associated protein 1 (INSM1) is a useful marker for pancreatic neuroendocrine tumor. ( 28849340 )
2017
24
Use of Volumetric Laser Endomicroscopy to Characterize a Duodenal Neuroendocrine Tumor. ( 28927838 )
2017
25
A 17-year-old male with a Small Bowel Neuroendocrine Tumor: flushing differential diagnosis. ( 28904734 )
2017
26
Long-Term Efficacy of S-1 Chemotherapy plus Administration of Octreotide for a Patient with Metastatic Neuroendocrine Tumor (Gastrinoma). ( 28626400 )
2017
27
Correction: Ablating all three retinoblastoma family members in mouse lung leads to neuroendocrine tumor formation. ( 28772359 )
2017
28
Ectopic adrenocorticotropic hormone syndrome in a case of duodenal neuroendocrine tumor presenting with liver metastasis. ( 28862247 )
2017
29
Growth rate of small pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: results from an endoscopic ultrasound based cohort study. ( 27975336 )
2017
30
Whole exome sequencing of thymic neuroendocrine tumor with ectopic ACTH syndrome. ( 27913610 )
2017
31
Anal Neuroendocrine Tumor Masquerading as External Hemorrhoids: A Case Report. ( 28270879 )
2017
32
Menin and Daxx Interact to Suppress Neuroendocrine Tumors through Epigenetic Control of the Membrane Metallo-Endopeptidase. ( 27872097 )
2017
33
Pulmonary neuroendocrine tumor in a female wolf (Canis lupus lupus). ( 28190820 )
2017
34
A cumulative effect involving malfunction of the PTH1R and ATP4A genes explains a familial gastric neuroendocrine tumor with hypothyroidism and arthritis. ( 28474257 )
2017
35
Impact of chromogranin A, differentiation, and mitoses in nonfunctional pancreatic neuroendocrine tumors a8o 2A cm. ( 28501118 )
2017
36
Hypermethylation of adjacent CpG sites is negatively correlated with the expression of lineage oncogene ASCL1 in pulmonary neuroendocrine tumors. ( 28621224 )
2017
37
An Elderly Man With Pancreatic Neuroendocrine Tumor and a Cavitary Right Upper Lobe Lung Mass. ( 28599947 )
2017
38
The role of 68Ga-DOTA-NOC PET/CT in evaluating neuroendocrine tumors: real-world experience from two large neuroendocrine tumor centers. ( 27922538 )
2017
39
68Ga-DOTATATE PET/CT in Primary Hepatic Neuroendocrine Tumor. ( 28005645 )
2017
40
Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study. ( 28444114 )
2017
41
Nonfunctional pancreatic neuroendocrine tumor masked as anemia: A case report. ( 28682910 )
2017
42
Computed Tomography Features Predictive of Lymph Node Involvement in Patients With a Nonfunctioning Pancreatic Neuroendocrine Tumor. ( 28787330 )
2017
43
Diffuse Enlargement of the Pancreas: An Unusual Radiologic Presentation of a Pancreatic Neuroendocrine Tumor. ( 28624649 )
2017
44
Improving quality of life in patients with pancreatic neuroendocrine tumor following peptide receptor radionuclide therapy assessed by EORTC QLQ-C30. ( 28864881 )
2017
45
Computed Tomography Features Predictive of Lymph Node Involvement in Patients With a Nonfunctioning Pancreatic Neuroendocrine Tumor. ( 28953200 )
2017
46
Renal Cell Carcinoma and a Pancreatic Neuroendocrine Tumor: A Coincidence or Instance of Von Hippel-Lindau Disease? ( 28794363 )
2017
47
Retrospective review of serotonergic medication tolerability in patients with neuroendocrine tumors with biochemically proven carcinoid syndrome. ( 28267211 )
2017
48
Insulin Expressing Pancreatic Neuroendocrine Tumor Associated With Intratumor Amyloidosis. ( 28648398 )
2017
49
Pancreatic neuroendocrine tumor with complete replacement of the pancreas by serous cystic neoplasms in a patient with von Hippel-Lindau disease: a case report. ( 28948530 )
2017
50
Pancreatic neuroendocrine tumor Grade 1 patients followed up without surgery: Case series. ( 28638801 )
2017

Variations for Neuroendocrine Tumor

Copy number variations for Neuroendocrine Tumor from CNVD:

7 (show all 16)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 46474 10 81600000 81900000 Gain or loss C10orf57 Neuroendocrine carcinoma
2 46475 10 81600000 81900000 Gain or loss PLAC9 Neuroendocrine carcinoma
3 46476 10 81600000 81900000 Gain or loss SFTPD Neuroendocrine carcinoma
4 98126 16 15400000 16800000 Duplication ABCC1 Neuroendocrine carcinoma
5 98127 16 15400000 16800000 Duplication ABCC6 Neuroendocrine carcinoma
6 98128 16 15400000 16800000 Duplication C16orf45 Neuroendocrine carcinoma
7 98129 16 15400000 16800000 Duplication C16orf63 Neuroendocrine carcinoma
8 98130 16 15400000 16800000 Duplication KIAA0430 Neuroendocrine carcinoma
9 98131 16 15400000 16800000 Duplication MYH11 Neuroendocrine carcinoma
10 98132 16 15400000 16800000 Duplication NDE1 Neuroendocrine carcinoma
11 109503 17 26446120 26728821 Microdeletion NF1 Neuroendocrine carcinoma
12 111157 17 35097918 35138441 Gain HER-2/neu Neuroendocrine carcinoma
13 122931 18 64000000 64040000 Deletion Neuroendocrine carcinoma
14 160839 22 16300000 24300000 Microdeletion Neuroendocrine carcinoma
15 226129 7 55054218 55242525 Gain EGFR Neuroendocrine carcinoma
16 248801 9 137300000 137400000 Duplication C9orf62 Neuroendocrine carcinoma

Expression for Neuroendocrine Tumor

Search GEO for disease gene expression data for Neuroendocrine Tumor.

Pathways for Neuroendocrine Tumor

Pathways related to Neuroendocrine Tumor according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.86 CALCA ENO2 NCAM1 NKX2-1 SYP
2 11.23 ASCL1 NCAM1 SYP
3 9.64 CCK GAST GRP

GO Terms for Neuroendocrine Tumor

Cellular components related to Neuroendocrine Tumor according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.76 CALCA CCK CHGA ENO2 GAST GRP
2 secretory granule GO:0030141 9.43 CHGA CHGB SCG2
3 extracellular region GO:0005576 9.32 CALCA CCK CHGA CHGB GAST GRP
4 terminal bouton GO:0043195 9.13 CALCA CCK SYP

Biological processes related to Neuroendocrine Tumor according to GeneCards Suite gene sharing:

(show all 12)
id Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.71 CALCA CHGB MEN1 SCG2
2 neuron migration GO:0001764 9.67 ASCL1 CCK NKX2-1
3 neuropeptide signaling pathway GO:0007218 9.65 CALCA GRP SSTR2
4 positive regulation of neural precursor cell proliferation GO:2000179 9.51 ASCL1 INSM1
5 forebrain neuron differentiation GO:0021879 9.43 ASCL1 NKX2-1
6 type B pancreatic cell differentiation GO:0003309 9.37 INSM1 MEN1
7 sympathetic ganglion development GO:0061549 9.32 ASCL1 INSM1
8 positive regulation of phospholipase C-activating G-protein coupled receptor signaling pathway GO:1900738 9.26 CHGA GRP
9 positive regulation of cAMP metabolic process GO:0030816 9.16 CHGA
10 cerebral cortex GABAergic interneuron differentiation GO:0021892 9.16 ASCL1 NKX2-1
11 noradrenergic neuron development GO:0003358 8.96 ASCL1 INSM1
12 adrenal chromaffin cell differentiation GO:0061104 8.62 ASCL1 INSM1

Molecular functions related to Neuroendocrine Tumor according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 neuropeptide hormone activity GO:0005184 9.13 CCK GRP NTS
2 hormone activity GO:0005179 9.02 CALCA CCK CHGB GAST SST

Sources for Neuroendocrine Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....